JP2019520071A - 急性重症大腸炎の処置応答を予測するための方法 - Google Patents

急性重症大腸炎の処置応答を予測するための方法 Download PDF

Info

Publication number
JP2019520071A
JP2019520071A JP2018565398A JP2018565398A JP2019520071A JP 2019520071 A JP2019520071 A JP 2019520071A JP 2018565398 A JP2018565398 A JP 2018565398A JP 2018565398 A JP2018565398 A JP 2018565398A JP 2019520071 A JP2019520071 A JP 2019520071A
Authority
JP
Japan
Prior art keywords
mir
hsa
responder
subject
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018565398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520071A5 (https=
Inventor
オジェ−ドゥニ，エリク
トレトン，クサヴィエ
ブニーク，ヨーラム
モリラ，イアン
ラーリー，ダヴィド
ヴェンラブ，ジル
ユザン，マチュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Universite Paris Diderot Paris 7
Universite Sorbonne Paris Nord
Centre Hospitalier Universitaire de Bordeaux
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Universite Paris Diderot Paris 7
Universite Sorbonne Paris Nord
Centre Hospitalier Universitaire de Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Universite Paris Diderot Paris 7, Universite Sorbonne Paris Nord, Centre Hospitalier Universitaire de Bordeaux filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of JP2019520071A publication Critical patent/JP2019520071A/ja
Publication of JP2019520071A5 publication Critical patent/JP2019520071A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Evolutionary Biology (AREA)
  • Software Systems (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2018565398A 2016-06-14 2017-06-14 急性重症大腸炎の処置応答を予測するための方法 Pending JP2019520071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305715.1 2016-06-14
EP16305715 2016-06-14
PCT/EP2017/064496 WO2017216206A1 (en) 2016-06-14 2017-06-14 Methods for predicting acute severe colitis treatment response

Publications (2)

Publication Number Publication Date
JP2019520071A true JP2019520071A (ja) 2019-07-18
JP2019520071A5 JP2019520071A5 (https=) 2020-05-21

Family

ID=56321880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018565398A Pending JP2019520071A (ja) 2016-06-14 2017-06-14 急性重症大腸炎の処置応答を予測するための方法

Country Status (4)

Country Link
US (2) US11060147B2 (https=)
EP (1) EP3469098A1 (https=)
JP (1) JP2019520071A (https=)
WO (1) WO2017216206A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022525824A (ja) * 2020-02-24 2022-05-20 中国科学院昆明▲動▼物研究所 トランスフェリンの発現量を検出するための試薬の、腸管免疫寛容不均衡疾患の診断試薬またはキットの調製における応用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501452A (ja) * 2008-08-29 2012-01-19 ヤンセン バイオテツク，インコーポレーテツド ２０個の遺伝子パネルを用いて潰瘍性大腸炎及び関連疾患を評価し治療するためのマーカー及び方法
JP2014500707A (ja) * 2010-09-27 2014-01-16 ザ チルドレンズ ホスピタル オブ フィラデルフィア 炎症性腸疾患の治療および診断に有用な組成および方法
JP2016515631A (ja) * 2013-04-05 2016-05-30 ヌメディー， インコーポレイテッド 消化器系疾患およびその他の疾患の処置

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US5132432A (en) 1989-09-22 1992-07-21 Molecular Probes, Inc. Chemically reactive pyrenyloxy sulfonic acid dyes
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5338854A (en) 1991-02-13 1994-08-16 Molecular Probes, Inc. Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5505928A (en) 1991-11-22 1996-04-09 The Regents Of University Of California Preparation of III-V semiconductor nanocrystals
US5262357A (en) 1991-11-22 1993-11-16 The Regents Of The University Of California Low temperature thin films formed from nanocrystal precursors
US6048616A (en) 1993-04-21 2000-04-11 Philips Electronics N.A. Corp. Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
US5571018A (en) 1994-11-23 1996-11-05 Motorola, Inc. Arrangement for simulating indirect fire in combat training
US5690807A (en) 1995-08-03 1997-11-25 Massachusetts Institute Of Technology Method for producing semiconductor particles
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
US5696157A (en) 1996-11-15 1997-12-09 Molecular Probes, Inc. Sulfonated derivatives of 7-aminocoumarin
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6617583B1 (en) 1998-09-18 2003-09-09 Massachusetts Institute Of Technology Inventory control
US6114038A (en) 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6855202B2 (en) 2001-11-30 2005-02-15 The Regents Of The University Of California Shaped nanocrystal particles and methods for making the same
AU4701200A (en) 1999-05-07 2000-11-21 Quantum Dot Corporation A method of detecting an analyte using semiconductor nanocrystals
US6225198B1 (en) 2000-02-04 2001-05-01 The Regents Of The University Of California Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process
US6306736B1 (en) 2000-02-04 2001-10-23 The Regents Of The University Of California Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process
WO2001071044A1 (en) 2000-03-22 2001-09-27 Quantum Dot Corporation Methods of using semiconductor nanocrystals in bead-based nucleic acid assays
JP2003535063A (ja) 2000-06-01 2003-11-25 ザ・ボード・オブ・リージェンツ・フォー・オクラホマ・ステート・ユニバーシティー 放射線医薬としてのナノ粒子のバイオコンジュゲート
AU2001279185B2 (en) 2000-08-04 2005-07-07 Molecular Probes, Inc. Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US6709929B2 (en) 2001-06-25 2004-03-23 North Carolina State University Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
EP1409240B1 (en) 2001-07-20 2012-05-09 Life Technologies Corporation Luminescent nanoparticles and methods for their preparation
EP1963531B1 (en) 2005-12-23 2011-09-21 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
US8986926B2 (en) 2005-12-23 2015-03-24 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
US8415102B2 (en) 2007-04-10 2013-04-09 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
US8126690B2 (en) 2007-05-18 2012-02-28 The Regents Of The University Of Michigan Algorithms to predict clinical response, adherence, and shunting with thiopurines
EP2156191A2 (en) 2007-06-15 2010-02-24 Smithkline Beecham Corporation Methods and kits for predicting treatment response in type ii diabetes mellitus patients
US20110117111A1 (en) 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US8519115B2 (en) 2008-08-14 2013-08-27 Nanostring Technologies, Inc. Stable nanoreporters
WO2012042516A2 (en) * 2010-09-29 2012-04-05 Mor Research Applications Ltd. Prognostic methods, compositions and kits for prediction of acute lymphoblastic leukemia (all) relapse

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501452A (ja) * 2008-08-29 2012-01-19 ヤンセン バイオテツク，インコーポレーテツド ２０個の遺伝子パネルを用いて潰瘍性大腸炎及び関連疾患を評価し治療するためのマーカー及び方法
JP2014500707A (ja) * 2010-09-27 2014-01-16 ザ チルドレンズ ホスピタル オブ フィラデルフィア 炎症性腸疾患の治療および診断に有用な組成および方法
JP2016515631A (ja) * 2013-04-05 2016-05-30 ヌメディー， インコーポレイテッド 消化器系疾患およびその他の疾患の処置

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. CROHNS COLITIS, vol. vol.8, suppl.1, JPN6020047787, 2014, pages 20 - 21, ISSN: 0004764143 *
J. CROHNS COLITIS, vol. vol.8, suppl.1，S85-S86, JPN6020047790, 2014, ISSN: 0004405567 *
PROG. MED., vol. vol.31, no.10, p.2377-2381, JPN6020047789, 2011, ISSN: 0004764145 *
日本小児栄養消化器肝臓学会雑誌, vol. vol.28, no.2, p.84-89, JPN6020047788, 2014, ISSN: 0004764144 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022525824A (ja) * 2020-02-24 2022-05-20 中国科学院昆明▲動▼物研究所 トランスフェリンの発現量を検出するための試薬の、腸管免疫寛容不均衡疾患の診断試薬またはキットの調製における応用
JP7321252B2 (ja) 2020-02-24 2023-08-04 中国科学院昆明▲動▼物研究所 トランスフェリンの発現量を検出するための試薬の、腸管免疫寛容不均衡疾患の診断試薬またはキットの調製における応用

Also Published As

Publication number Publication date
WO2017216206A1 (en) 2017-12-21
EP3469098A1 (en) 2019-04-17
US20220098665A1 (en) 2022-03-31
US11060147B2 (en) 2021-07-13
US20190136324A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
JP6867659B2 (ja) アルツハイマー病又は軽度認知症の検出を補助する方法
US11230736B2 (en) Methods for assessing pregnancy outcome
US20150275290A1 (en) Non-invasive method for detecting a fetal chromosomal aneuploidy
EP2663650B1 (en) Methods for predicting the outcome of a cancer in a patient by analysing gene expression
CN105067822A (zh) 用于食管癌诊断的标志物
CN110747269A (zh) 用于pcos诊断的颗粒细胞生物标志物及其筛选方法和诊断试剂盒
US20250333795A1 (en) Composition for amplifying flt3 gene, and uses thereof
IL285031A (en) Diagnosis of inflammatory bowel diseases
CN110945143A (zh) 利用下一代测序方法的靶蛋白的聚类定量方法及其用途
US20220098665A1 (en) Methods for predicting acute severe colitis treatment response
WO2024230768A1 (en) Efficient digital measurement of long nucleic acid fragments
KR102096499B1 (ko) 대장암 진단 또는 재발 예측을 위한 마이크로rna-3960 및 이의 용도
US20180010194A1 (en) Methods for the Diagnosis of Pancreatic Cancer
WO2017102902A1 (en) Micrornas as predictive biomarkers of type 1 diabetes
US11021756B2 (en) MiRNA markers for the diagnosis of osteosarcoma
KR102229647B1 (ko) 신장이식 환자의 급성거부반응 진단용 miRNA 바이오 마커 및 이의 용도
WO2016092045A1 (en) Methods and kits for predicting medically refractory acute severe colitis
KR102876333B1 (ko) 패혈증 진단 또는 예후 예측용 신규 바이오마커 및 이의 용도
WO2019229489A1 (en) Use of mir-146a-5p and mir-186 as biomarkers of osteoarthritis
LU102676B1 (en) A Biomarker for Severe Asthma and Application Thereof
WO2024229279A2 (en) Use of circulating microrna profiles for identification of brca1 or brca2 mutations
Sciabica et al. High–throughput, quantitative multiplex gene expression assay accelerates the validation of breast cancer biomarkers
NZ750396B2 (en) Biomarkers for inflammatory bowel disease
NZ750396A (en) Biomarkers for inflammatory bowel disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200409

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211012

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20211208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220214

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220214

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220301

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220328

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220329

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220513

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220517

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230411